← SynDRA
VEMURAFENIB
SynDRA canonical compound SYN0024127 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | BRAF |
|---|
| Mechanism of action | RAF inhibitor |
|---|
| Indication | melanoma |
|---|
| Disease area | oncology |
|---|
All known targets
- BRAF
- RAF1
- ARAF
- MAP2K5
- RIPK3
- RIPK2
- PTK6
- Map2k4
- MAP4K5
- MAP3K20
- KRAS
- ASPH
Mechanisms of action (all sources)
- RAF inhibitor
- BRAF INHIBITOR
- Serine/threonine-protein kinase B-raf inhibitor
- RAF1 INHIBITOR
- BRAF MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MAP2K1
- TNK2
- RET
- SYK
- NEK11
- CHRM1
- CHRM2
- CHRM3
- EGFR
- NEK2
- MAP2K2
- YES1
- NQO2
- OLA1
- NUAK2
- NTRK1
- NR3C1
- NR1I2
- NPY1R
- OPRD1
- NLK
- NEK9
- NEK7
- NEK6
- NEK5
- NEK4
- NEK3
- OPA1
- PHKG2
- PGRMC1
- OPRM1
- PGR
- PFKP
- PEBP1
- PIM1
- PDXK
- PDGFRB
- PDE4D
- PDE3A
- PAK4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- GAMT
- GNMT
- HNMT
- IFNG
- KSYK
- NNMT
- NSD2
- PNMT
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Cytochrome P450 1A2 Inhibitors
- P-Glycoprotein Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- ZELBORAF
- Zelboraf
- PLX-4032
- RO 5185426
- RG 7204
- zelboraf
- Ro 51-85426
- PLX4032
- RG-7204
- RO-5185426
- RO-51-85426
- RG7204
- RO5185426
- Zelboraf (TN)
- Vemurafenib (BRAF inhibitor)
- PLX 4032
- Vemurafenib (PLX4032, RG7204)
- Vemurafenib (PLX4032)
- 207SMY3FQT
- CHEBI:63637
- MFCD18074504
- NSC761431
- Vemurafenib;PLX-4032
- Vemurafenib [USAN]
- Vemurafenib [USAN:INN]
- UNII-207SMY3FQT
- vemurafenibum
- HSDB 8143
- 3og7
- VEMURAFENIB [MI]
- Vemurafenib; PLX4032
- VEMURAFENIB [INN]
- VEMURAFENIB [JAN]
- PLX4032 - Vemurafenib
- VEMURAFENIB [VANDF]
- VEMURAFENIB [MART.]
- VEMURAFENIB [WHO-DD]
- SCHEMBL298931
Reported adverse events
- Arthralgia
- Cough
- Fatigue
- Headache
- Hypersensitivity
- Neoplasm
- Neutropenia
- Pancreatitis
- Photosensitivity reaction
- Rash
- Rash papular
- Decreased appetite
Look up VEMURAFENIB in the interactive SynDRA portal →